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Abstract
Purpose Recent studies have demonstrated that ser-
um/plasma DNA and RNA molecules in addition to pro-
teins can serve as biomarkers. Elevated levels of these
nucleic acids have been found not only in acute, but also in
chronic conditions, including autoimmune diseases. The
aim of this study was to assess cell-free DNA (cfDNA)
levels in sera of rheumatoid arthritis (RA) patients com-
pared to controls.
Methods cfDNA was extracted from sera of patients with
early and established RA, relapsing-remitting multiple
sclerosis patients (RRMS) and healthy subjects, and its
concentration was determined by quantitative PCR using
two amplicons, Alu115 and b-actin205, corresponding to
Alu repetitive elements and the b-actin single-copy gene,
respectively. Serum DNase activity was measured by a
single radial enzyme diffusion method.
Results Reduced levels of cfDNA were observed in
patients with established RA in comparison with healthy
controls, early RA patients and RRMS patients. There were
no significant differences in cfDNA concentration between
healthy controls, early RA and RRMS patients. Total
DNase activity appeared to be similar in the sera of all
tested groups.
Conclusions Our results demonstrate that cfDNA levels
are strongly reduced in the sera of established RA patients,
which is not caused by changes in DNase activity. Mea-
surement of cfDNA can distinguish established RA patients
from early RA patients. Thus, cfDNA may serve as a
biomarker in RA.
Keywords Autoimmune diseases  Rheumatoid arthritis 
Cell-free DNA  Biomarker
Introduction
Rheumatoid arthritis (RA) is a chronic heterogeneous
autoimmune disease characterized by progressive joint
destruction. Serological tests, most notably the detection of
anti-citrullinated protein antibodies (ACPA) and rheuma-
toid factor (RF), play an important role in diagnosing RA.
ACPA were found in up to 75 % of RA patients [1]. RF is
present in 60–90 % of patients with established RA (esRA)
and in up to 50 % of patients with early RA (eRA) [2]. In
contrast to ACPA the disease specificity of RF is relatively
low, with 3–5 % of healthy adults showing the presence of
RF in their serum, which increases to 10–30 % in the
elderly [3]. RF was also found in patients with other
autoimmune and infectious diseases.
Earlier it was suggested that the sooner RA patients are
treated the better their prognosis is [4]. Although the
introduction of ACPA and RF tests has greatly contributed
to improving the early diagnosis of RA, additional
molecular markers are needed, e.g., to identify
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seronegative patients, to differentiate between disease
phenotypes, to predict responsiveness to treatment and to
improve prognosis.
Circulating cell-free DNA (cfDNA), which is defined as
extracellular DNA occurring in blood serum or plasma, has
been widely studied and is considered as a potential bio-
marker for the detection and monitoring of various human
diseases such as stroke [7, 8], myocardial infarction [9],
sepsis [10] and acute pancreatitis [11], as well as some
chronic conditions such as cancer [12]. Significantly higher
cfDNA levels were found in the serum of cancer patients
with advanced disease stages or metastases [13] and it has
been previously shown that circulating cfDNA carries
tumor-specific genetic alterations [14].
Circulating cfDNA molecules are present in only limited
amounts in blood of healthy individuals, since dying cells
and remnants of dead cells are efficiently removed, mainly
in the liver [5, 6]. The origin and exact mechanism of
cfDNA release are still controversial. Accumulation of
cfDNA in plasma/serum might result from an excessive
release of DNA caused by massive cell death, inefficient
elimination of dead cells, extracellular DNA traps formed
during inflammation, or a combination of these. Thus, the
concentration of plasma/serum cfDNA might reflect the
magnitude of cell damage and inflammation.
It is not known whether cfDNA can be used as a rapid
and sensitive marker of RA. In analogy with cancer, ele-
vated levels of circulating cfDNA have been hypothesized
to occur in autoimmune diseases [15]. Alteration of cfDNA
levels has been reported for autoimmune diseases such as
systemic lupus erythematosus (SLE), systemic sclerosis,
Sjo¨gren’s syndrome [16] and RA [17]. The aim of the study
described here was to quantify cfDNA levels in sera of
eRA and esRA patients using both single-copy gene and
Alu repetitive element analyses.
Method
Patients
Sera from RA patients were obtained from four different
centers. Samples from esRA patients were collected at the
Radboud University Nijmegen Medical Center (n = 9), at
the St. Maartenskliniek in Nijmegen (n = 10) and at the
Catharina Hospital in Eindhoven (n = 8). Samples from 22
eRA patients were obtained from the Leiden Early Arthritis
Clinic, an inception cohort of patients with recent onset
arthritis (symptoms duration\2 years) that was started at
the Department of Rheumatology of the Leiden University
Medical Center in 1993 and was described in detail pre-
viously [18]. Samples from 20 eRA patients were collected
at the Erasmus Medical Center in Rotterdam. As controls, a
cohort of relapsing remitting multiple sclerosis patients
(RRMS; collected at the Multiple Sclerosis Center Nij-
megen; n = 44), and a group of healthy control individuals
(collected at the Sanquin Blood Bank in Nijmegen;
n = 50) were included. All RA patients fulfilled the
American College of Rheumatology 1987 revised criteria
for the classification of RA. Patient sera were used in
accordance with the code of conduct of research with
human material in The Netherlands. All subjects gave
informed consent. Serum samples were aliquoted and
stored at -80 C prior to further use. Patient characteristics
are summarized in Supplementary Table S1.
Serum cfDNA isolation and quantification
Sera of 29 control subjects, 39 eRA, 26 esRA and 33
RRMS patients were used for cfDNA isolation. cfDNA was
extracted from 200 lL of serum using the QIAamp DNA
Blood Mini kit (Qiagen) according to the manufacturer’s
manual and was eluted with 50 lL of water. The amounts
of isolated cfDNA were determined using real-time PCR
analyses. Two different targets were chosen for quantifi-
cation: a housekeeping gene, b-actin, and Alu repetitive
elements. Three independent analyses were performed.
Each PCR reaction was performed in a total volume of
10 lL containing 1 9 GoTaq master mix (Promega),
0.75 lM of each primer, and 0.5–1 lL of cfDNA solution.
The amplicons resulted in 115-bp (Alu) and 205-bp (b-
actin) fragments [see Table 1 for primer sequences; 19].
Cycle threshold (Ct) values were measured with a StepOne
Plus qPCR machine (software version 2.2; Applied
Biosystems; Warrington, UK). Thermocycling was per-
formed at 95 C for 10 min (b-actin205) or for 2 min
(Alu115), followed by 40 cycles at 95 C for 15 s and
60 C for 60 s. Each sample was analyzed in duplicate and
negative controls were included in each run. Melting curve
analysis was performed to confirm the specificity of PCR
products. The absolute DNA concentration was calculated
according to the standard curves obtained with parallel
analyses of human genomic DNA (Qiagen) with concen-
trations varying from 0.005 to 10 ng/lL.
The Ct values obtained for cfDNA samples were con-
verted to serum cfDNA concentrations using the following
formula [20]:
cfDNA½  ¼ Q
VPCR
 VDNA
Vext
with [cfDNA] being the cfDNA concentration, Q/VPCR the
cfDNA concentration as deduced from the standard curve,
VDNA the volume of the isolated cfDNA solution, and Vext
the volume of serum used for cfDNA extraction.
24 Autoimmun Highlights (2015) 6:23–30
123
DNase activity assay
Sera of 50 control subjects, 16 esRA and 44 RRMS patients
were used for DNase activity assay. To determine serum
total DNase activity, a single radial enzyme diffusion
(SRED) method was used [21]. This method is based on the
principle that DNases present in serum samples are able to
diffuse radially through a thin layer of agarose, which
contains DNA, react with the DNA and hydrolyze it.
Agarose gels (1.4 %; MetaPhor Agarose, Lonza) were
prepared in buffer containing 20 mM Tris–HCl, pH 7.5,
2 mM MgCl2, 2 mM CaCl2, 100 ng/mL DNA from herring
testes (Sigma-Aldrich) and GelStar stain (Cambrex). Wells
(approx. 0.5 mm diameter) were punched in the gel. A
standard curve was generated by serial dilutions of DNase I
enzyme (Qiagen). Two microlitre of DNase I solution
(concentration series) or serum samples were added to the
wells. The gels were incubated in a humidified dark
chamber at 37 C for 24 h. GelStar fluorescence was
visualized with a Doc-Print II System (Vilbert Lourmat).
DNase activity was quantified by measuring the diameter
of the non-stained circles resulting from DNA hydrolysis.
Statistical analysis
A statistical comparison of the data for the different groups
was performed using GraphPad Prism software. For non-
parametric comparisons, univariate analysis by the Mann–
Whitney U test was performed. Differences were consid-
ered significant at p\ 0.05. The diagnostic sensitivity and
specificity were determined by receiver operator charac-
teristic (ROC) analysis.
Results
Serum cfDNA levels
To determine the levels of cfDNA in sera, a quantitative
real-time PCR approach was chosen for two different
amplicons, one for Alu repeats and another for the b-actin
gene. In addition to sera from esRA patients, sera from
healthy individuals and from RRMS patients were used as
controls; RRMS was chosen as another autoimmune dis-
ease with a different disease onset and with different
treatment strategies. Alu repeats are highly repetitive
sequences, which are found in approximately 106 copies in
the human genome, whereas b-actin is encoded by a single-
copy gene. As shown in Figs. 1a and 2a, the cfDNA levels
determined by the Alu amplicon (median 39 ng/mL; range
10–403 ng/mL) and by the b-actin amplicon (median
14 ng/mL; range 6–37 ng/mL) appeared to be much lower
in the sera from esRA patients (n = 26) than in those from
healthy controls (n = 26) and from RRMS patients
(n = 33) (p\ 0.0001). RRMS sera showed similar levels
of cfDNA as the healthy control sera (Figs. 1a, 2a; median
233 ng/mL (range 47–6900 ng/mL) and 206 ng/mL (range
42–899 ng/mL), respectively, for Alu115, and 188 ng/mL
(range 18–3804 ng/mL) and 177 ng/mL (range 31–920 ng/
mL), respectively, for b-actin205).
To assess whether the Alu115- and b-actin205-based
qPCR assay for cfDNA can serve to discriminate RA
patients from control individuals, receiver operating char-
acteristic (ROC) analysis was applied (Figs. 1b, 2b,
respectively). This analysis revealed that the area under the
curve (AUC) values were high (AUC = 0.914 for Alu115
and AUC = 0.994 for b-actin205). It is important to note
that the RA samples analyzed came from three distinct
cohorts of esRA patients, which makes it unlikely that the
differences observed are due to trivial factors associated
with the handling and storage of the samples. The Alu115
and b-actin205 qPCR analyses do not seem to be useful to
discriminate RRMS patients from healthy controls.
Previously, ACPA have been reported to discriminate
between two distinct populations of RA patients [22, 23].
Therefore, we also compared cfDNA levels in patients with
anti-cyclic citrullinated peptide (anti-CCP)-positive RA
and anti-CCP-negative RA. No significant differences were
observed between the levels of cfDNA in anti-CCP2-pos-
itive and anti-CCP2-negative RA sera (Fig. 3).
The early diagnosis of RA and start of treatment is
beneficial for patients to prevent or abrogate ongoing joint
damage. Biomarkers which facilitate the early diagnosis of
RA are needed in addition to ACPA. To study whether
cfDNA levels were already decreased at the early stages of
the disease, we determined cfDNA levels also in sera from
eRA patients (n = 34) using the Alu115 and b-actin205
primer sets and performed additional analyses with mate-
rial from healthy controls (n = 29). The results demon-
strated that there was no significant difference between
serum cfDNA levels of healthy individuals and eRA
patients (Fig. 4). Comparison of eRA (n = 39) and esRA
(n = 24) samples, however, showed much lower serum
cfDNA levels for esRA patients than the levels in the eRA
Table 1 Primers used for
qPCR reaction
Forward primers (50–30) Reverse primers (50–30)
Alu115 CCTGAGGTCAGGAGTTCGAG CCCGAGTAGCTGGGATTACA
b-actin205 GAGACCTTCAACACCCCAGCC GGATCTTCATGAGGTAGTCAG
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samples (Fig. 5). Thus, the reduction of cfDNA levels
appears to occur after disease onset.
Serum DNase activity
The reduced serum cfDNA levels in esRA might be
explained by elevated levels and/or activity of nucleases
present in the sera. Deoxyribonuclease I (DNase I) is one of
the predominant DNases in human serum [24]. Deficiency
in DNase I enzyme, and the resulting enhanced levels of
cfDNA associated with nuclear antigens, promotes sus-
ceptibility to autoimmune disorders [25]. To investigate
whether the reduced serum cfDNA levels were due to
enhanced DNase activity in the sera, a radial enzyme dif-
fusion method was carried out with sera from healthy
controls (n = 50) and from esRA (n = 16) and RRMS
(n = 44) patients. The sera were loaded on a gel containing
Fig. 1 Alu repeat-based detection of serum cfDNA. DNA was
isolated from sera of healthy individuals (CTR), RA and RRMS
patients and subjected to qPCR analysis with primers for the Alu115
amplicon (a). The bars indicate the median with interquartile range.
**indicates p\ 0.0001; ns indicates not significant. A ROC analysis
was performed to discriminate RA patients from healthy controls (b)
Fig. 2 b-actin gene-based detection of serum cfDNA. DNA isolated
from sera of healthy individuals (CTR), RA and RRMS patients was
subjected to qPCR analysis with primers for the b-actin205 amplicon
(a). The bars indicate the median with interquartile range. **indicates
p\ 0.0001; ns indicates not significant. A ROC analysis was
performed to discriminate RA patients from healthy controls (b)
Fig. 3 cfDNA concentration does not correlate with anti-CCP2
autoantibody status. Comparison of circulating Alu115 and b-
actin205 DNA in sera from patients with anti-CCP2-positive
(CCP?) and anti-CCP2-negative (CCP-) RA. The bars indicate
the median with interquartile range. ns indicates not significant
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DNA, and, after incubation at 37 C, DNA hydrolysis by
nucleases present in the sera was visualized using a fluo-
rescent dye. The results showed that no significant differ-
ences in total DNase activity between these groups were
observed (Fig. 6). Thus, the reduced levels of cfDNA in
esRA sera do not seem to be due to elevated DNase
activities.
Discussion
In the present study, we found reduced levels of serum
cfDNA in established RA compared to healthy controls,
early RA patients and RRMS patients. Lower levels of
cfDNA have been reported before to occur in sera from
SLE as well as in sera from RA patients in comparison with
healthy subjects [26]. In addition, when nucleosome
plasma levels were assessed by ELISA, nucleosomes
appeared to be hardly detectable in the plasma of patients
with RA in comparison with SLE patients [27]. Paradoxi-
cally, other studies showed a substantial increase in cfDNA
concentration in plasma or serum of RA patients [16, 17,
28]. Leon et al. [28] reported that relatively high levels of
cfDNA were found in patients with more severe symptoms
who had active RA for less than 10 years, whereas patients
with longer duration of disease showed a lower level of
cfDNA. Elevated DNA levels were found more frequently
in patients seronegative for rheumatoid factor (RF). Zhong
Fig. 4 cfDNA in early RA. DNA isolated from sera of healthy subjects (CTR) and eRA patients was analysed by qPCR using Alu115 primers
(a) or b-actin205 primers (b). ns indicates not significant
Fig. 5 Comparison of cfDNA concentration in sera of eRA and esRA patients. Serum cfDNA was purified and analysed by qPCR using Alu115
primers (a) or b-actin205 primers (b)
Fig. 6 DNase activity in sera from healthy individuals (CTR), RA
and RRMS patients. The SRED method was used to determine the
DNase activity in the sera. Sera were applied to wells in a 1.4 %
agarose gel containing DNA and a DNA-staining dye and incubated
in a humidified chamber at 37 C for 24 h. Subsequently, the radius
of the non-fluorescent area surrounding each well was measured
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et al. [17] found higher concentrations of cfDNA in serum
and plasma of RA patients in comparison with healthy
controls. These conflicting data on serum cfDNA levels in
RA may at least in part be explained by the use of different
techniques (for example, qPCR, ELISA or UV-spec-
trophotometry) and the different DNA targets chosen to
perform the analyses. The PCR assay measures only
amplifiable DNA, i.e., DNA fragments with a sufficient
size and devoid of simple sequence repeats, whereas the
assays based on spectrophotometry detect the total nucleic
acid content such as dsDNA, ssDNA, and RNA. In addi-
tion, differences in the state of disease progression and/or
activity at the time of sampling may have affected the
results, as indicated by the differences observed for eRA
and esRA. Moreover, differences in sample processing and
storage might have introduced preanalytical biases. How-
ever, Sjoholm et al. [29] demonstrated that plasma and
serum samples that were stored for 10–30 years produced
reliable results when the cfDNA was extracted and
amplified with PCR. In this respect we should also stress
that samples collected in different centers were used in our
study, which reduces the chance for such biases. Never-
theless, replication studies with distinct clinical cohorts are
needed to support our findings. In addition, the analysis of
larger groups may increase the statistical significance of
our data.
We also observed slight overrepresentation of DNA
quantified by the Alu repeats in sera in comparison with
DNA quantified by the b-actin qPCR (see Fig. 3). How-
ever, the Alu115 and b-actin205 concentrations were
highly correlated with each other for all groups tested
(Supplementary Fig. S1). Our results are in agreement with
previously reported observations. The proportion of Alu
repeats relative to the b-globin gene was larger in serum
DNA than in lymphocyte DNA, both in control subjects
and in cancer patients [30]. In addition, overrepresentation
of Alu repeats in serum cfDNA, in comparison with the
complete human genome, was shown before for 50 healthy
individuals [31]. The consistently higher levels of qPCR-
quantified DNA resulting from the Alu repeat analysis
compared to the b-actin gene might be due to the frag-
mentation of DNA in serum. The chance that a complete
Alu115 amplicon is present in a single DNA fragment is
not only higher as a result of its size (115 basepairs com-
pared to 205 basepairs for b-actin), but also due to the
presence of multiple copies of the Alu115 amplicon in the
human genome.
The exact mechanism by which DNA is released in
blood is unknown. Previously, it has been demonstrated
that the DNA in serum/plasma is predominantly
hematopoietic in origin [32]. Four processes that may lead
to the generation of circulating DNA have been suggested:
cell death (necrosis or apoptosis) or tissue injury, active
secretion of DNA by leukocytes, enucleation (a process in
which the nuclei are expelled by erythroblasts during the
course of maturation) and NETosis (a process in which
neutrophils discharge extracellular traps).
Because we observed reduced levels of cfDNA in esRA
patients, but not in eRA patients, it is tempting to speculate
about a role for drug treatment. Methotrexate (MTX) is the
most common disease-modifying anti-rheumatic drug
(DMARD) used to treat RA. It reduces inflammation and
inhibits enzymes involved in nucleoside/nucleotide meta-
bolism. Previously, it has been shown that patients with
RA, treated with MTX, display low concentrations of cir-
culating purines and pyrimidines, with consequent reduced
availability for DNA and RNA synthesis and cell prolif-
eration [33]. Therefore, it will be very interesting to
investigate whether the decrease of cfDNA in sera of esRA
patients correlates with MTX treatment and dosage. In this
respect, it is also important to note that the RRMS patients,
which are only infrequently treated with MTX (only as a
second line treatment), do not show altered cfDNA levels.
None of the RRMS patients analyzed received MTX. The
following processes might also cause the reduced levels of
cfDNA in esRA patients: (1) increase of cfDNA degrada-
tion/elimination due to increased levels of circulating
nuclease activity. However, we did not observe differences
in the activity of serum nucleases between eRA and esRA
patients and control individuals. (2) Increase of cfDNA
degradation/elimination due to increased levels of serum
anti-dsDNA antibodies. These antibodies can influence the
level of circulating nucleosomes. An inverse correlation
between anti-dsDNA antibody levels and concentrations of
circulating DNA in SLE patients was observed [26]. RA
patients can also develop anti-dsDNA antibodies induced
by anti-TNFa biological therapies. They are usually of low
avidity and are detectable transiently after treatment [34].
(3) Increase of cfDNA degradation/elimination due to
enhanced metabolic activity and the generation of reactive
oxygen species (ROS) by blood cells. It has been shown
that DNA degradation products are elevated in leukocytes
and sera of RA patients [35]. Moreover, increased oxida-
tive enzyme activity along with decreased antioxidant
levels in sera and synovial fluid of RA patients was
observed. Higher levels of ROS in sera of esRA patients
can change cfDNA degradation and lead to decreased
cfDNA concentrations in sera. (4) Decreased apoptosis/
necrosis of blood cells. Altered apoptosis susceptibility of
peripheral blood mononuclear cells for various systemic
autoimmune diseases has been previously shown. The
presence of activated peripheral blood T lymphocytes with
impaired apoptosis, resulting in long-lived T cells periph-
erally in RA was reported [36]. Reduced apoptosis has
been also detected in synovial tissues from patients with
RA [37]. (5) Different susceptibility to degradation of
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various forms of circulating DNA such as shed cells,
apoptotic bodies, nucleosomes, other nucleoproteins, and
free DNA which exists in serum/plasma. The various forms
of cfDNA might differ between healthy control and RA
patients and the fates of different cfDNA forms are
unknown.
In conclusion, the quantitative changes in serum cfDNA
may be helpful as disease progression markers. Potential
correlations between cfDNA levels and clinical features,
such as disease activity, erosiveness and response to treat-
ment, still need to be explored. It will be interesting to
investigate whether the changes in cfDNA levels are affec-
ted by drugs used to treat RA patients. To further explore
these possibilities, longitudinal studies will be necessary to
get more insight in the time course of the reduction of
cfDNA levels and the effects of drugs on these changes.
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